A newer, smarter vaccine delivery system for COVID-19 vaccines
Official title: Evaluation of iDMV-1.0: A Single Dose Self-Amplifying Vaccine for SARS-CoV-2
Funded at University of Vermont & St Agric College · NIH-11406290 · Data updated 2026-11-12
This grant explores how lipid nanoparticles used in vaccines influence the immune response and how to design better vaccines for people.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Vermont & St Agric College NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project start | September 15, 2018 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $206,015 |
| NIH project number | 5P20GM125498-09 |
| Project ID | NIH-11406290 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals who receive vaccines or are interested in how vaccine components affect immune responses.
✕Less likely to help
Patients not directly involved in vaccine studies or those not receiving any experimental components may not experience immediate benefits.
What this research studies
The project looks at how the tiny fat-based carriers in vaccines affect immune signals, using cell studies and cutting-edge gene-editing screens. It aims to map which cellular pathways respond to these delivery vehicles and which cells sense the immune activation. By understanding these interactions, researchers hope to tailor vaccine components to achieve desired immune outcomes. The work focuses on translating basic findings into safer and more effective next-generation vaccines.
Why it matters
Potential benefit: Improved vaccine designs with safer and stronger immune responses for people.
How similar studies have gone: Previous lipid nanoparticle studies have shown that delivery vehicles can shape immune responses, but this project aims to map precise pathways for improved design.
Where this research is happening
-
University of Vermont & St Agric College
Burlington, United States Active
Researchers
- Principal investigator: Majumdar, Devdoot — University of Vermont & St Agric College
- Study coordinator: Majumdar, Devdoot
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.